Journal
HEALTH AFFAIRS
Volume 36, Issue 12, Pages 2046-2053Publisher
PROJECT HOPE
DOI: 10.1377/hlthaff.2017.0890
Keywords
-
Funding
- National institute of Drug Abuse [T32-DA007293]
- predoctoral Department of Mental Health Scholar at the Johns Hopkins Bloomberg School of Public Health
Ask authors/readers for more resources
People in the US criminal justice system experience high rates of opioid use disorder, overdose, and other adverse outcomes. Expanding treatment is a key strategy for addressing the opioid epidemic, but little is known about whether the criminal justice system refers people to the highest standard of treatment: the use of the opioid agonist therapies methadone or buprenorphine. We used 2014 data from the national Treatment Episode Data Set to examine the use of agonist treatment among justice-involved people referred to specialty treatment for opioid use disorder. Only 4.6 percent of justice-referred clients received agonist treatment, compared to 40.9 percent of those referred by other sources. Of all criminal justice sources, courts and diversionary programs were least likely to refer people to agonist treatment. Our findings suggest that an opportunity is being missed to promote effective, evidence-based care for justice-involved people who seek treatment for opioid use disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available